Mutation burden of narrowband ultraviolet B phototherapy (NB-UVB) in human skin: relevance to NB-UVB lifetime exposures and skin cancer surveillance
British Journal of Dermatology · 2025
DOI: 10.1093/bjd/ljaf173 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Dermatology, 2025. Verfasst von Joanna C Fowler und 9 weiteren Autor:innen. Beteiligte Einrichtung: Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK. Hauptthemen laut MEDLINE: Ultraviolet Therapy, Mutation, Skin Neoplasms, Psoriasis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Psoriasis Association, Medical Research Council, Wellcome Trust.
Abstract (Originalsprache)
Background
Ultraviolet radiation (UVR) is used as treatment for psoriasis and other skin diseases, but UVR can induce DNA mutations that may lead to skin cancer development. While skin cancers have been documented in patients treated with phototherapy, a limited number of epidemiological studies have examined the incidence of skin cancer in people receiving narrowband ultraviolet B (NB-UVB) treatment. Information on the mutagenicity of NB-UVB would help inform about the potential skin cancer risks of this treatment.
Objectives
To determine the mutation burden in human skin resulting from a NB-UVB treatment course and to use this data to estimate the total number of NB-UVB exposures whereupon skin cancer surveillance should begin.
Methods
Biopsies of normal skin were obtained before and after a course of NB-UVB from 16 patients with psoriasis. Epidermal DNA was sequenced using nanorate sequencing (NanoSeq) to determine the mutational signatures and mutation burden from NB-UVB.
Results
The NB-UVB treatment course increased the number of mutations in skin. Median increase in mutation burden was 0.55 substitutions per Mb in infrequently sun-exposed (buttock; n = 14) skin and 0.89 substitutions per Mb in frequently sun-exposed (forearm; n = 10) skin (P < 0.001). Change in mutation burden due to NB-UVB ranged from 1.16- to 10.50-fold in buttock skin and from 0.93- to 2.33-fold in forearm skin. This increase was mainly attributable to UVR exposure-linked mutational signatures, SBS7a and SBS7b, with some evidence that mutational burden was related to the genetic background of the individual. Modelling the change in mutation burden from NB-UVB relative to minimal erythema dose (MED) in comparison with average mutation burden in keratinocyte skin cancers allowed estimation of total lifetime exposures at which patients are likely to require skin cancer surveillance; for patients with a MED equal to 2 standard erythemal doses (SEDs), skin cancer surveillance should be offered at 422, 165 and 58 NB-UVB exposures for those receiving low, typical and high levels of sun exposure, respectively.
Conclusions
A treatment course of NB-UVB causes UVR-induced mutations in the healthy skin of patients with psoriasis. Relating mutation burden to MED and sun behaviour habits allows estimation of when to begin skin cancer surveillance according to total lifetime NB-UVB exposures.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK.
- Dermatopharmacology, University of Southampton, Southampton General Hospital, Southampton, UK.
- Dermatology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
- Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
- Human Development and Health, University of Southampton, Southampton General Hospital, Southampton, UK.
- Institute for Life Sciences, University of Southampton, Southampton, UK.
ORCID-Profile: George Coltart, Chester Lai, John W Holloway, Matthew J J Rose-Zerilli, Brian Diffey, Philip H Jones, Eugene Healy
Förderung
- Psoriasis Association
- Medical Research Council
- Wellcome Trust
- Medical Research Council Clinical Academic Research Partnership
Zitieren
APA
Fowler, J. C., Sood, R. K., Coltart, G., Lai, C., Nadarajah, N., Holloway, J. W., Rose-Zerilli, M. J. J., Diffey, B., Jones, P. H., & Healy, E. (2025). Mutation burden of narrowband ultraviolet B phototherapy (NB-UVB) in human skin: relevance to NB-UVB lifetime exposures and skin cancer surveillance. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljaf173
Vancouver
Fowler JC, Sood RK, Coltart G, Lai C, Nadarajah N, Holloway JW, et al. Mutation burden of narrowband ultraviolet B phototherapy (NB-UVB) in human skin: relevance to NB-UVB lifetime exposures and skin cancer surveillance. British Journal of Dermatology. 2025. doi:10.1093/bjd/ljaf173
BibTeX
@article{Fowler2025,
author = {Fowler, Joanna C and Sood, Roshan K and Coltart, George and Lai, Chester and Nadarajah, Noeline and Holloway, John W and Rose-Zerilli, Matthew J J and Diffey, Brian and Jones, Philip H and Healy, Eugene},
title = {Mutation burden of narrowband ultraviolet B phototherapy (NB-UVB) in human skin: relevance to NB-UVB lifetime exposures and skin cancer surveillance},
journal = {British Journal of Dermatology},
year = {2025},
doi = {10.1093/bjd/ljaf173}
}
EUVIMED